Chimeric proteins that induce effects directed against viruses

Neisseria meningitidis The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-no...

Full description

Saved in:
Bibliographic Details
Main Authors Cruz, Lisset Hermida, Diaz, Rayner Rodriguez, Vazquez, Laura Lazo, Morales, Aida Zulueta, Abarrategui, Carlos Lopez, Prado, Iris Valdes, Rodriguez, Richardo de la C. Silva, Santiago, Glay Chinea, Nieto, Gerardo Enrique Guillen, Tirado, Maria Guadalupe Guzman, Vazquez, Beatriz de la Caridad Sierra, Perez, Raul Rafael Espinosa
Format Patent
LanguageEnglish
Published 24.05.2011
Online AccessGet full text

Cover

More Information
Summary:Neisseria meningitidis The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.